- Home
- IDN vs MRSN Comparison
IDN vs MRSN Comparison
Compare IDN & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDN
- MRSN
- Stock Information
- Founded
- IDN 1994
- MRSN 2001
- Country
- IDN United States
- MRSN United States
- Employees
- IDN N/A
- MRSN N/A
- Industry
- IDN Computer Software: Prepackaged Software
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- IDN Technology
- MRSN Health Care
- Exchange
- IDN Nasdaq
- MRSN Nasdaq
- Market Cap
- IDN 46.8M
- MRSN 40.7M
- IPO Year
- IDN 1999
- MRSN 2017
- Fundamental
- Price
- IDN $2.83
- MRSN $0.32
- Analyst Decision
- IDN Buy
- MRSN Buy
- Analyst Count
- IDN 2
- MRSN 3
- Target Price
- IDN $3.00
- MRSN $4.00
- AVG Volume (30 Days)
- IDN 47.0K
- MRSN 2.3M
- Earning Date
- IDN 05-13-2025
- MRSN 05-15-2025
- Dividend Yield
- IDN N/A
- MRSN N/A
- EPS Growth
- IDN N/A
- MRSN N/A
- EPS
- IDN N/A
- MRSN N/A
- Revenue
- IDN $19,997,000.00
- MRSN $40,497,000.00
- Revenue This Year
- IDN $7.60
- MRSN N/A
- Revenue Next Year
- IDN $10.02
- MRSN N/A
- P/E Ratio
- IDN N/A
- MRSN N/A
- Revenue Growth
- IDN 5.77
- MRSN 9.88
- 52 Week Low
- IDN $1.92
- MRSN $0.26
- 52 Week High
- IDN $4.46
- MRSN $3.50
- Technical
- Relative Strength Index (RSI)
- IDN 61.62
- MRSN 41.87
- Support Level
- IDN $2.47
- MRSN $0.35
- Resistance Level
- IDN $2.87
- MRSN $0.44
- Average True Range (ATR)
- IDN 0.17
- MRSN 0.04
- MACD
- IDN 0.03
- MRSN -0.00
- Stochastic Oscillator
- IDN 92.86
- MRSN 8.48
About IDN Intellicheck Inc.
Intellicheck Inc is a trusted industry leader in technology solutions that stop identity theft and fraud with real-time identification authentication and age verification. The products of the company include solutions for preventing identity fraud across any industry delivered via smartphone, tablet, POS integration or other electronic devices.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.